<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are characterized by increased prevalence with aging, a genetic predisposition, and comparable pathological features in the islet and brain (amyloid derived from amyloid beta protein in the brain in <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> and islet amyloid derived from islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> in the pancreas in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>) </plain></SENT>
<SENT sid="1" pm="."><plain>Evidence is growing to link precursors of <z:mpath ids='MPATH_34'>amyloid deposition</z:mpath> in the brain and pancreas with the pathogenesis of <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>Given these similarities, we questioned whether there may be a common underlying mechanism predisposing to islet and cerebral amyloid </plain></SENT>
<SENT sid="3" pm="."><plain>To address this, we first examined the prevalence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in a community-based controlled study, the Mayo Clinic <z:hpo ids='HP_0002511'>Alzheimer Disease</z:hpo> Patient Registry (ADPR), which follows patients with <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> versus control subjects without <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition to this clinical study, we performed a pathological study of autopsy cases from this same community to determine whether there is an increased prevalence of islet amyloid in patients with <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> and increased prevalence of cerebral amyloid in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Patients who were enrolled in the ADPR (<z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> n = 100, non-<z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> control subjects n = 138) were classified according to fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> concentration (FPG) as nondiabetic (FPG &lt;110 mg/dl), impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> (IFG, FPG 110-125 mg/dl), and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (FPG &gt;126 mg/dl) </plain></SENT>
<SENT sid="6" pm="."><plain>The mean slope of FPG over 10 years in each case was also compared between <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> and non-<z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> control subjects </plain></SENT>
<SENT sid="7" pm="."><plain>Pancreas and brain were examined from autopsy specimens obtained from 105 humans (first, 28 cases of <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> disease vs. 21 non-<z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> control subjects and, second, 35 subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> vs. 21 non-type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> control subjects) for the presence of islet and brain amyloid </plain></SENT>
<SENT sid="8" pm="."><plain>Both type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (35% vs. 18%; P &lt; 0.05) and IFG (46% vs. 24%; P &lt; 0.01) were more prevalent in <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> versus non-<z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> control subjects, so 81% of cases of <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> had either type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> or IFG </plain></SENT>
<SENT sid="9" pm="."><plain>The slope of increase of FPG with age over 10 years was also greater in <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> than non-<z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> control subjects (P &lt; 0.01) </plain></SENT>
<SENT sid="10" pm="."><plain>Islet amyloid was more frequent (P &lt; 0.05) and extensive (P &lt; 0.05) in patients with <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> than in non-<z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> control subjects </plain></SENT>
<SENT sid="11" pm="."><plain>However, diffuse and <z:hpo ids='HP_0100256'>neuritic plaques</z:hpo> were not more common in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> than in control subjects </plain></SENT>
<SENT sid="12" pm="."><plain>In cases of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> when they were present, the duration of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> correlated with the density of diffuse (P &lt; 0.001) and <z:hpo ids='HP_0100256'>neuritic plaques</z:hpo> (P &lt; 0.01) </plain></SENT>
<SENT sid="13" pm="."><plain>In this community cohort from southeast Minnesota, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and IFG are more common in patients with <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> than in control subjects, as is the pathological hallmark of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, islet amyloid </plain></SENT>
<SENT sid="14" pm="."><plain>However, there was no increase in brain plaque formation in cases of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, although when it was present, it correlated in extent with duration of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="15" pm="."><plain>These data support the hypothesis that patients with <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> are more vulnerable to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and the possibility of linkage between the processes responsible for loss of brain cells and beta-cells in these diseases </plain></SENT>
</text></document>